Skip to content
Clinical Trials – home

ARTEMISIA VULGARIS: A Comprehensive Guide for Patients

Artemisia Vulgaris is an investigational medicinal product. No trial currently registered in Europe lists it – that can change as new trials are authorised, and it may be under study elsewhere.

In short

This article discusses recent clinical trials investigating the use of Artemisia vulgaris (mugwort) extracts in allergy testing and immunotherapy. These studies aim to evaluate the effectiveness and safety of various formulations containing Artemisia vulgaris for diagnosing and treating allergies, particularly allergic rhinitis and rhinoconjunctivitis caused by mugwort pollen.

At a glance

Study Focus
Efficacy and safety of Artemisia vulgaris (mugwort) extracts in allergy testing and immunotherapy
Target Conditions
Moderate to severe allergic rhinitis/rhinoconjunctivitis due to mugwort pollen
Administration Methods
Skin prick tests, sublingual immunotherapy, subcutaneous immunotherapy
Primary Endpoints
Changes in Combined Symptom and Medication Score (CSMS), safety assessments
Secondary Endpoints
Quality of life improvements, changes in specific IgE levels, nasal provocation test results
Participant Criteria
Adults 18-65, confirmed mugwort allergy, moderate to severe symptoms, specific health requirements
Study Phases
Phase II-III clinical trials

What is Artemisia Vulgaris?

Artemisia vulgaris, commonly known as mugwort or common wormwood, is a plant species that has been used in traditional medicine for centuries. In modern medicine, it is primarily used as an allergen extract for diagnostic purposes and potential treatment of allergies.

Medical Uses

The primary medical use of Artemisia vulgaris in the context provided is for allergy diagnosis and potentially for immunotherapy. It is used in the form of a skin prick test solution to diagnose allergies to this specific plant.

Artemisia vulgaris is classified under the ATC code V01AA02, which stands for "Allergen extracts, grass pollen". This classification suggests that it is used similarly to grass pollen extracts in allergy testing and treatment.

Administration Method

The Artemisia vulgaris extract is administered as a solution for skin-prick test. This means it is applied to the skin in a controlled manner to observe if an allergic reaction occurs. The typical dose is 1 drop, applied cutaneously (on the skin).

Allergen Testing

Skin prick testing is a method used by allergists to determine if a patient is allergic to specific substances. During the test, a small amount of the Artemisia vulgaris extract is placed on the skin, usually on the forearm or back. The skin is then pricked through the drop with a small, sterile probe. If you're allergic to Artemisia vulgaris, a small, itchy bump (wheal) surrounded by redness (flare) will appear at the test site within about 15 minutes.

Precautions and Considerations

While the information provided doesn't specify precautions for this particular allergen extract, it's important to note that skin prick tests should be performed under medical supervision. Patients with a history of severe allergic reactions should inform their healthcare provider before undergoing such tests.

It's also worth noting that Artemisia vulgaris is part of a broader panel of allergen tests that may include other substances such as house dust mites, animal dander, and various pollens. Your healthcare provider will determine which specific allergens to test based on your medical history and symptoms.

Questions people often ask

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).